Tisagenlecleucel治疗B-ALL后CD19阳性与CD19阴性复发的决定因素
该研究纳入51例接受tisagenlecleucel治疗的复发/难治B细胞前体急性淋巴细胞白血病患者,中位年龄17岁。第28天完全缓解率为96%,中位随访15.5个月时18个月累积复发率、无事件生存率和总生存率分别为51%、44%和74%。淋巴清除前高疾病负荷(MRD≥10^-2)和第28天可检测MRD与CD19阴性复发风险增加相关,低疾病负荷和B细胞再生障碍丧失与CD19阳性复发风险增加相关。
要点
- 淋巴清除前MRD≥10^-2和第28天可检测MRD预测CD19阴性复发。
- 低疾病负荷和B细胞再生障碍丧失预测CD19阳性复发。
- 第28天可检测MRD和B细胞再生障碍丧失定义高危复发患者。
核心结论
- 既往blinatumomab治疗和高肿瘤负荷相关因素增加复发风险并缩短生存。
- 淋巴清除前高疾病负荷和第28天可检测MRD与CD19阴性复发风险增加相关。
- 低疾病负荷和B细胞再生障碍丧失与CD19阳性复发风险增加相关。
研究设计与样本
- 研究报告51例接受tisagenlecleucel治疗的复发/难治B细胞前体急性淋巴细胞白血病患者,中位年龄17岁。
主要发现
- 第28天完全缓解率为96%。
- 中位随访15.5个月时,18个月累积复发率、无事件生存率和总生存率分别为51%、44%和74%。
- 既往blinatumomab增加第28天早期失败风险。
- 高肿瘤负荷相关因素(细胞因子释放综合征发生)和既往blinatumomab与累积复发率增加及无事件生存率和总生存率缩短相关。
- 淋巴清除前高疾病负荷(MRD≥10^-2,SHR 10.4,p=0.03)和第28天可检测MRD(SHR 7.2,p=0.006)与CD19阴性复发风险增加相关。
临床怎么用
- 第28天可检测MRD和B细胞再生障碍丧失定义高危复发患者,需额外干预。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Tisagenlecleucel therapy has shown promising efficacy for relapsed/refractory (R/R) B-cell precursor acute lymphoblastic leukemia (BCP-ALL). However, relapses occur in 30-50% of patients. Determinants for CD19pos versus CD19neg relapses are poorly characterized. We report on 51 patients with R/R BCP-ALL (median age 17 years) infused with tisagenlecleucel after lymphodepletion. Complete remission rate at D28 was 96%. Prior blinatumomab increased the risk of early failure at D28. The 18-month cumulative incidence of relapse (CIR), event-free survival (EFS), and overall survival (OS) were 51%, 44%, and 74%, respectively, at a median follow-up of 15.5 months. Factors associated with a high tumor burden (occurrence of cytokine release syndrome) and prior blinatumomab were associated with an increased CIR, and a shorter EFS and OS. Pre-lymphodepletion high disease burden (MRD ≥ 10-2, SHR 10.4, p = 0.03) and detectable MRD at D28 (SHR 7.2, p = 0.006) correlated with an increased risk of CD19neg relapse. Low disease burden (SHR 5.3, p = 0.03) and loss of B-cell aplasia (BCA) (SHR 21.7, p = 0.004) predicted an increased risk of CD19pos relapses. These data highlight the impact of prior therapy on patient outcome. Finally, detectable MRD at D28 and loss of BCA both define patients at high risk of relapse for whom additional interventions are needed.
引用
- Dourthe ME, Rabian F, Yakouben K, et al. Determinants of CD19-positive vs CD19-negative relapse after tisagenlecleucel for B-cell acute lymphoblastic leukemia. Leukemia. 2021. PMID: 34002027. doi:10.1038/s41375-021-01281-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。